Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy
(APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse
events, cardiovascular and cerebrovascular adverse events and reducing clinical related
bleeding events in the patients with acute coronary syndrome (ACS) who are not the
predominant coronary artery disease after percutaneous coronary intervention (PCI).